What is Chimerix?
Headquartered in Durham, North Carolina, Chimerix is a specialized biopharmaceutical entity focused on the discovery, development, and commercialization of therapeutic candidates. The company's core research centers on nucleoside analogs, with a lead candidate, brincidofovir, currently positioned to address serious viral infections in immunocompromised populations, including stem cell transplant recipients. Beyond its lead program, Chimerix maintains a robust pipeline, including preclinical and Phase II clinical-stage assets targeting norovirus, HIV, and hepatitis B. By leveraging strategic partnerships with organizations like BARDA, the company effectively bridges the gap between early-stage research and commercial-ready medical solutions.
How much funding has Chimerix raised?
Chimerix has raised a total of $237.9M across 8 funding rounds:
Series A
$1M
Series B
$3.1M
Unspecified
$36.1M
Series C
$11M
Series D
$23.1M
Other Financing Round
$16.1M
Other Financing Round
$45M
Stock Offering
$102.5M
Series A (2002): $1M with participation from Asset Management Company
Series B (2003): $3.1M led by Sanderling Ventures
Unspecified (2003): $36.1M supported by National Institutes of Health
Series C (2004): $11M featuring Sanderling Ventures
Series D (2007): $23.1M backed by Canaan Partners, Alta Partners, Frazier Healthcare Partners, and Sanderling Ventures
Other Financing Round (2009): $16.1M with participation from Canaan Partners, Sanderling Ventures, and Alta Partners
Other Financing Round (2011): $45M led by Morningside Group, Pappas Ventures, New Leaf Venture Partners, Frazier Healthcare Partners, Canaan Partners, Sanderling Ventures, and Alta Partners
Stock Issuance/Offering (2013): $102.5M, investors not publicly disclosed
Key Investors in Chimerix
Sanderling Ventures
A pioneering investment firm founded in 1979, specializing in building new biomedical companies through early-stage financing and active management.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages.
Alta Partners
A prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for Chimerix?
Looking ahead, Chimerix is poised to leverage its historical capital infusion to accelerate its clinical development programs. The company's strategic roadmap emphasizes the transition of its nucleoside analog portfolio through critical regulatory milestones. By maintaining a disciplined approach to R&D and fostering high-value collaborations, Chimerix aims to solidify its market position as a leader in antiviral therapeutics. Future growth will likely be driven by the successful progression of its Phase II assets and the potential expansion of its commercial footprint, ensuring that its innovative medicines reach the patient populations that require them most.
See full Chimerix company page
